We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    PROPEL-36
Previous Study | Return to List | Next Study

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04969861
Recruitment Status : Terminated (Nektar Therapeutics made the decision to discontinue the bempegaldesleukin program based on three negative studies. SFJ Pharmaceuticals, Inc. and Nektar Therapeutics, in consultation with the study IDMC, have decided to discontinue PROPEL-36.)
First Posted : July 21, 2021
Last Update Posted : June 1, 2022
SFJ Pharmaceuticals, Inc.
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Nektar Therapeutics

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Terminated
Actual Primary Completion Date : April 22, 2022
Actual Study Completion Date : April 22, 2022
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 October 24, 2022
(Canceled on October 25, 2022)
November 21, 2022